BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28888335)

  • 1. Dramatic relapse of seizures after everolimus withdrawal.
    Mingarelli A; Vignoli A; La Briola F; Peron A; Giordano L; Banderali G; Canevini MP
    Eur J Paediatr Neurol; 2018 Jan; 22(1):203-206. PubMed ID: 28888335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
    BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
    Jancic J; Duric V; Ivancevic N; Nikolic B; van den Anker JN; Samardzic J
    Curr Med Chem; 2016; 23(37):4260-4269. PubMed ID: 27739368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin and rapalogs for tuberous sclerosis complex.
    Sasongko TH; Ismail NF; Zabidi-Hussin Z
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
    Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
    Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice.
    Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T
    Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
    Lechuga L; Franz DN
    Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
    [No Abstract]   [Full Text] [Related]  

  • 12. Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex.
    Fukumura S; Watanabe T; Takayama R; Minagawa K; Tsutsumi H
    J Child Neurol; 2015 Aug; 30(9):1192-5. PubMed ID: 25143481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
    Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
    Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
    Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Efficacy of Everolimus for Refractory Seizures in Childhood Onset Epilepsy with Tuberous Sclerosis Complex].
    Okanishi T; Fujimoto A; Nishimura M; Baba S; Itamura S; Okanari K; Enoki H
    Brain Nerve; 2019 Jun; 71(6):611-616. PubMed ID: 31171758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
    Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
    Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
    Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
    Song X; Said Q; Tran O; Krueger DA; Bissler J
    Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.
    Davies M; Saxena A; Kingswood JC
    Orphanet J Rare Dis; 2017 Feb; 12(1):35. PubMed ID: 28202028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
    Jiang T; Du J; Raynald ; Wang J; Li C
    World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.